SCHEMBL3770901

SCHEMBL3770901

COc1ccc(N2CCN(CC(=O)N3CCN(C4CCCC4)CC3)CC2)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
KDM4E B2RXH2 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
TSHR P16473 1/20 0.53
KMT2A Q03164 1/20 0.53
RAB9A P51151 2/20 0.50
POLB P06746 1/20 0.50
GAA P10253 1/20 0.48
CBX7 O95931 1/20 0.46
CDYL2 Q8N8U2 1/20 0.46
CDYL Q9Y232 1/20 0.46
ACHE P22303 1/20 0.45
DRD2 P14416 1/20 0.45
ADRA1D P25100 1/20 0.45
ADRA1A P35348 1/20 0.45
ADRA1B P35368 1/20 0.45
KDM2B Q8NHM5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773990 0.99 ALDH1A1 (0.54) ALDH1A1KDM4ETDP1TSHRKMT2A
SCHEMBL3768900 0.86 KDM4E (0.71) ALDH1A1KDM4ETDP1TSHRRAB9A
SCHEMBL3773931 0.86 KDM4E (0.51) ALDH1A1KDM4ETDP1RAB9APOLB
SCHEMBL3762993 0.84 ALDH1A1 (0.60) ALDH1A1KDM4ETDP1TSHRKMT2A
SCHEMBL3780644 0.84 ALDH1A1 (0.55) ALDH1A1KDM4ETDP1TSHRKMT2A
SCHEMBL3769405 0.84 KDM2B (0.54) ALDH1A1KDM4ETSHRKMT2ARAB9A
SCHEMBL3773794 0.84 HSD17B10 (0.49) ALDH1A1TDP1TSHRKMT2ARAB9A
SCHEMBL3773498 0.83 TSHR (0.56) ALDH1A1KDM4ETSHRKMT2APOLB
SCHEMBL3774818 0.83 ALDH1A1 (0.62) ALDH1A1KDM4ETDP1TSHRKMT2A
SCHEMBL3762896 0.83 KDM4E (0.52) ALDH1A1KDM4ETDP1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885KDM4E 534/4885TDP1 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.